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Introduction
Despite widespread advances in cancer diagnostics and treatment, ovarian cancers
continue to have high mortality, with 5-year survival rates remaining near 45% since
the mid-1990s.1 Hyperthermia represents one promising approach for peritoneal cancer therapy, as this modality has the capacity to kill cancer cells in a direct fashion
and also indirectly stimulates an anticancer immune response.2–6 In seeking to apply
hyperthermia therapy to dispersed peritoneal tumors, however, delivering thermal
doses to malignant cells in a precise and controlled fashion represents a substantial
technical barrier.
Iron oxide nanoparticles (IONPs) have a decades-long history as heating mediators
in hyperthermia,7 and advances in nanoparticle fabrication and functionalization have
fueled further interest in this research space.8–10 Preferential accumulation of IONPs
in the tumor, however, remains a challenge in balancing efficacy and safety.8,11 One
recent study co-opted tumor-associated peritoneal phagocytes to selectively deliver
IONPs in an ovarian cancer model.6 In other work, luteinizing hormone–releasing
hormone (LHRH) peptide was used as an IONP-targeting moiety for ovarian cancer
cells overexpressing the LHRH receptor.12 Similarly, many ovarian cancers overexpress folate receptor alpha (FOLRα),13,14 and this fact has been leveraged to selectively
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Abstract: Active molecular targeting has become an important aspect of nanoparticle
development for oncology indications. Here, we describe molecular targeting of iron oxide
nanoparticles (IONPs) to the folate receptor alpha (FOLRα) using an engineered antibody fragment (Ffab). Compared to control nanoparticles targeting the non-relevant botulinum toxin, the
Ffab-IONP constructs selectively accumulated on FOLRα-overexpressing cancer cells in vitro,
where they exhibited the capacity to internalize into intracellular vesicles. Similarly, Ffab-IONPs
homed to FOLRα-positive tumors upon intraperitoneal administration in an orthotopic murine
xenograft model of ovarian cancer, whereas negative control particles showed no detectable
tumor accumulation. Interestingly, Ffab-IONPs built with custom 120 nm nanoparticles exhibited
lower in vitro targeting efficiency when compared to those built with commercially sourced
180 nm nanoparticles. In vivo, however, the two Ffab-IONP platforms achieved equivalent tumor
homing, although the smaller 120 nm IONPs were more prone to liver sequestration. Overall,
the results show that Ffab-mediated targeting of IONPs yields specific, high-level accumulation
within cancer cells, and this fact suggests that Ffab-IONPs could have future utility in ovarian
cancer diagnostics and therapy.
Keywords: nanoparticle targeting, antibody fragment, biodistribution, ovarian cancer
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target IONPs via functionalization with the cognate folic acid
ligand.15 Monoclonal antibodies and antibody fragments have
also been used to selectively target IONPs to ovarian cancer
cells,16,17 but to date there is no report of antibody-mediated
IONP targeting to the FOLRα surface protein. Antibody targeting of FOLRα might offer performance advantages over
targeting with the folic acid ligand, as the former should be
highly specific to FOLRα, while the latter is also bound with
high affinity by folate receptors beta and gamma, and can
interfere with uptake of circulating folate in patients.18,19
In the current research, we describe the development and
characterization of IONPs functionalized with an engineered
fab fragment of Farletuzumab, a humanized monoclonal
antibody that has demonstrated tumor-inhibitory effects in
pre-clinical models20–22 and in clinical trials.23 Tumor-specific
homing of the antibody fragment Farletuzufab (Ffab)-targeted IONPs was assessed both in vitro and in vivo, and the
results were compared to negative control particles targeting
an irrelevant protein. In aggregate, these studies demonstrate
the performance advantage of IONPs that actively target the
FOLRα cancer marker.

Materials and methods
Cells lines and culture conditions
KB cells, derived from a human squamous cell carcinoma
of the oral cavity, were obtained as a gift from Dr Philip S
Low at Purdue University (West Lafayette, IN, USA). These
KB cells were found to produce disseminated peritoneal
tumors that are representative of advanced ovarian cancer
in humans. The cells were maintained as a monolayer in
folate-free Roswell Park Memorial Institute (RPMI) 1640
medium (Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% fetal bovine serum (FBS) at 37°C in a
humidified atmosphere consisting of 5% CO2 and 95% air.
Cells were harvested with 0.25% trypsin, suspended, and
spun down at 1,200 rpm prior to re-suspension and use in
subsequent experiments.

Construction of Ffab and anti-botulinum
toxin fab fragments
Ffab and negative control anti-botulinum toxin fab fragment
(Bfab) were reformatted from their corresponding full length
immunoglobulin G (IgG) monoclonal antibody sequences,
which are available from the literature.24,25 Coding sequences
for the variable and constant regions of the heavy and
light chains from respective full length IgGs were reverse
translated, codon optimized for expression in mammalian
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cells, and synthesized by DNA 2.0 (DNA 2.0 Inc., Menlo
Park, CA, USA). Both Ffab and Bfab heavy chains were
designed to carry an engineered cysteine tag at their respective C-termini for subsequent site-specific conjugation to
maleimide-polyethylene glycol 2 (PEG2)-biotin (Thermo
Fisher Scientific) or nanoparticles. Ffab and Bfab light- and
heavy-chain constructs were individually sub-cloned into
the CMVR VRC01 expression vector (National Institutes of
Health [NIH] acquired immunodeficiency syndrome [AIDS]
Reagent Program, Germantown, MD, USA).

Expression, extraction, and purification
of Ffab protein
CMVR VRC01 expression vectors separately harboring Ffab
light chain and heavy chain or Bfab light chain and heavy
chain were co-transfected into suspension HEK 293 cells
using polyethylenimine (Polysciences Inc, Warrington, PA,
USA) as previously described.26 Secreted Ffab and Bfab
were clarified through centrifugation at 8,000 rpm at 4°C
for 15 minutes on an Avanti® J 25 centrifuge (Beckman
Coulter Inc, Brea, CA, USA). The resulting supernatants
were filtered through a 0.45 µm filter to remove any residual
cell debris and other large particles before loading onto a
fast protein liquid chromatography (FPLC) affinity column
for purification.
Affinity purification was performed on a pre-packed
5 mL KappaSelect column from GE Healthcare Bio-Sciences
Corporation (Piscataway, NJ, USA) as suggested by manufacturer instructions. Fabs were eluted with 100 mM glycine
at pH 2.7 in 2 mL Eppendorf tubes prefilled with 50 µL of
1 M tris(hydroxymethyl)aminomethane (Tris), 5 mM ethylenediaminetetraacetic acid (EDTA). The purification process
was automated on an AKTA™ FPLC system (GE Healthcare
Bio-Sciences Corp). Purified proteins were subjected to a
second step size exclusion chromatography column using
Superdex® 75 (GE Healthcare Bio-Sciences Corp). Final
products were eluted in phosphate-buffered saline (PBS)
and stored at -20°C until used.
Reductive activation and chemical conjugation of the
purified fabs to maleimide-PEG2-biotin (Thermo Fisher
Scientific) were performed as described previously.26 Briefly,
maleimide-PEG2-biotin was added to a final concentration of
2 mM (10 to 1 molar excess for maleimide-PEG2-biotin to
proteins). The conjugation reaction was allowed to proceed
for 2 hours at room temperature. The excess of maleimidePEG2-biotin was removed by buffer exchange through
a HiTrap™ desalting column using PBS pH 7.0, and the resultant Bfab and Ffab conjugates (Bfab-maleimide-PEG2-biotin
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and Ffab-maleimide-PEG2-biotin) were stored at -20°C until
further use. Purified and conjugated proteins were analyzed
using non-reduced and reduced sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) conditions and
stained with Coomassie blue. Protein constructs were verified
further using electrospray ionization time-of-flight (ESITOF) liquid chromatography mass spectrometry (Agilent
Technologies, Santa Clara, CA, USA).

Affinity measurement of Ffab
The affinity of Ffab protein was analyzed using enzymelinked immunosorbent assay (ELISA) and biolayer interferometry on the ForteBio Octet® Red instrument (ForteBio,
Menlo Park, CA, USA). For ELISA, commercial rFOLR1-his
protein (Sino Biological Inc, Beijing, People’s Republic of
China) reconstituted at 50 µg/mL (1.9 µM) in water was
diluted in coating buffer (100 mM sodium carbonate at pH
9.4) to 100 ng/mL (3 nM). Two 96-well Immulon™ 4HBX
high protein binding plates (Thermo Fisher Scientific) were
coated with 100 µL of rFOLR1-his at 4°C for 16 hours. Bindings with serial dilutions of Ffab and Bfab (0–200 nM) were
performed as previously described.26 The monovalent affinity
of Ffab was measured by biolayer interferometry. Briefly,
rFOLR1-his was loaded in a 96-well plate at different concentrations (1.56–25 nM). Ffab was coupled to streptavidin
biosensor tips (ForteBio) at 20 µg/mL and immersed into
the rFOLR1-his dilutions. Ffab association and dissociation
rates and equilibrium affinity were determined using software
provided with the instrument.

Ffab cell-binding studies
For live cell binding, KB cells were harvested from T250 flasks
(USA Scientific, Ocala, FL, USA) and seeded into a 96-well
microplate at 50,000 cells per well using PBS containing 2%
FBS. Different concentrations of Ffab or Bfab (0–200 nM)
were added to cells and incubated at room temperature on
a shaker (150 rpm) for 1 hour. Plates were centrifuged at
1,200 rpm for 5 minutes and washed twice with cold PBS
containing 2% FBS using a vacuum unit. Cells were incubated
with Phycolink® Streptavidin-R-Phycoerythrin (Prozyme,
Hayward, CA, USA) at room temperature for 30 minutes,
centrifuged, and washed as in previous step. Cells were
resuspended in PBS, 2% FBS, and analyzed on a MacsQuant®
instrument (Miltenyi Biotec Inc, Auburn, CA, USA).

Production of carboxymethyl dextran IONPs
Commercially available ferric chloride (FeCl3⋅6H2O), ferrous sulfate (FeSO4⋅7H2O), 25 wt% ammonium hydroxide
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solution, NaNO3, and NaOH were purchased from VWR
International (Radnor, PA, USA). Carboxymethyl-dextran
(CMD) 40 kDa was purchased from TdB Consultancy AB
(Uppsala, Sweden). All reactants were used as received without further purification. Magnetic nanoparticles (MNPs) with
CMD embedded in their structure, as described by Kekalo
and Baker,27 were also obtained. Briefly, 10% solutions of
salts of Fe and Fe(III) were precipitated by ammonia solution
in the presence of excess of polysaccharide. The mixture was
placed on a sand bath and heated up to 70°C. Then, NaOH
and NaNO3 were added to oxidize Fe and maintain alkali
media (pH .10). The temperature was raised up to 100°C
at a speed of 10°C/hour. The resulting solution was spun at
5,000 rpm for 15 minutes to remove large aggregates. The
remaining MNPs were purified using an LS magnetic column
separator (Miltenyi Biotec).

Nanoparticle characterization
Transmission electron micrographs of the nanoparticles
were taken using an FEI Technai F20ST field emission gun
transmission electron microscope operated at 200 kV. Five
hundred MNPs from three different locations on a grid were
used to produce frequency vs particle size histograms.

Antibody-IONP conjugation
and characterization
The 25 nm core size CMD-coated nanoparticles were
obtained from the Dartmouth nanoparticle core facility, and
the 100 nm core size aminodextran-coated bionized nanoferrite (BNF) nanoparticles were purchased from Micromod
Partikeltechnologie GmbH (Rostock, Germany). Prior to use,
CMD and BNF-IONPs were purified using MACS® separation LS columns (Miltenyi Biotec) and eluted with sterile
water. CMD nanoparticles were maleimide functionalized
by adding N-(2-Aminoethyl)maleimide and 1-ethyl-3-(3dimethylaminopropyl)carboiimide (EDC) (both purchased
from Sigma-Aldrich Co, St Louis, MO, USA) in 100-fold
molar excess and incubating for 2 hours at room temperature in 100 mM 2-morpholinoethanesulfonic acid (MES)
pH 6.3. BNF nanoparticles were maleimide functionalized
by adding sulfo-GMBS ( N-[γ-maleimobutyryloxy] sulfosuccinimide ester) (Thermo Fisher Scientific) in 100-fold
molar excess and incubating at room temperature for 2 hours
in 100 mM sodium phosphate buffer pH 7.2. The excess
N-(2-Aminoethyl)maleimide, EDC, and sulfo-GMBS were
removed by buffer exchange with 30 mM MES pH 6.5 (for
CMD particles) or 30 mM MES, 5 mM EDTA pH 6.5 (for
BNF particles) using MACS separation LS columns.
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Purified Ffab and Bfab were reduced with 20 mM cysteine
as described previously,26 followed by buffer exchange on
HiTrap desalting columns (GE Healthcare Bio-Sciences
Corp) with 30 mM MES pH 6.5 (for CMD particles) or
30 mM MES, 5 mM EDTA pH 6.5 (for BNF particles).
CMD-cysteine-reduced Ffab and Bfab were added to the
maleimide-functionalized CMD and BNF-IONPs at a 1:10
(w/w) ratio and incubated at room temperature for 16 hours
at 4°C on a shaker set at 125 rpm. This ratio was empirically determined to yield high-binding IONP conjugates
and reproducible conjugation results. The unbound protein
was then removed using MACS separation LS columns and
magnetic field. All processes were performed in a sterile
environment using sterile and endotoxin-free buffers. Micro
BCA assay (Thermo Fisher Scientific) was used to determine
the amount of Ffab and Bfab covalently bound to IONPs, as
described previously.26
The hydrodynamic Z-average diameters (HDD) and zeta
potentials (mV) of IONP-Fab conjugates were measured
using a Zetasizer Nano ZS (Malvern Instruments, Malvern,
UK). For measuring the HDD, the IONPs were diluted to
0.05 mg/mL in PBS. For the determination of zeta potential,
the IONPs were diluted to a concentration of 0.2 mg/mL in
10 mM NaCl.

determined from a standard curve of iron (FeCl3) in identically processed samples.
For cellular binding, KB cells were seeded at 100,000 cells
per well on a 48-well plate (Corning Incorporated, Corning,
NY, USA) and allowed to attach overnight. Old medium
was removed and replaced with 300 µL of fresh medium
containing 35 µg/mL of CMD-Ffab (0.6 nM), CMD-Bfab
(0.6 nM), BNF-Ffab (0.035 nM), or BNF-Bfab (0.035 nM).
Cells were incubated at 37°C for 8 hours, and unbound
nanoparticles were removed by washing three times with
PBS. Cells were treated with 100 µL of sodium hydroxide
(NaOH), placed on a shaker in a 37°C room for 1 hour, and
the ferrozine assay was performed as described above in this
section, except 300 µL of ferrozine reagent was added.26
For transmission electron microscopy, KB cells treated
with IONPs for 8 hours were washed with PBS and fixed
with a fixative solution (3% glutaraldehyde and 1% paraformaldehyde in 0.1 M sodium cacodylate, pH 7.4) at room
temperature for 15 minutes. After incubation, cells were
briefly centrifuged and fresh fixative solution was added,
followed by an additional 16 hours incubation at 4°C. Fixed
cells were submitted to the Dartmouth Medical Electron
Microscope Facility for imaging.

In vitro IONP-fab binding studies

Peritoneal tumor model and IONP
biodistribution

The commercial rFOLR1-his (Sino Biological Inc) was
diluted in PBS to 500 ng/mL (20 nM), and a 96-well Immulon
4HBX high-protein binding plate (Thermo Fisher Scientific)
was coated with 100 µL of rFOLR-his at 4°C for 16 hours.
Coating buffer was removed by aspiration and replaced with
300 µL of blocking buffer (2% bovine serum albumin [BSA;
w/v] in 1× PBS, pH 7.4). Serial dilutions of Ffab-CMD and
Bfab-CMD (0–5 nM) or Ffab-BNF and Bfab-BNF (0–1 nM)
in sample diluents (0.1% BSA [w/v] in PBS, pH 7.4) were
added and incubated at room temperature for 1 hour. Nanoparticle uptake was measured using a ferrozine-based iron
assay as described previously.26 Briefly, plates were washed
three times using washing buffer (Tris buffer saline [TBS],
0.05% Tween20 [v/v]). After washing, 100 µL of 1.4 M HCl
was added to each well, and plates were sealed and heated
at 70°C for 2 hours. Plates were centrifuged at 200 rpm
to settle liquids, 100 µL of ferrozine reagent (6.5 mM
ferrozine, 13 mM neocuproine, and 2 M ascorbic acid diluted
in 5 M ammonium acetate) were added to each well, and
plates were shaken for 5 minutes. Plates were read at 562 nm
(using a SpectraMax ® 190; Molecular Devices LLC,
Sunnyvale, CA, USA), and the amount of iron per well was

All mice were cared for according to approved Institutional
Animal Care and Use Committee (IACUC) animal protocol.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were originally
obtained from Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA, and were bred at the Geisel School
of Medicine at Dartmouth. At 5–6 weeks old, female mice
were injected intraperitoneally (IP) on day 0 with 2×106 KB
cells in 400 µL PBS. Within 2 weeks, tumors started growing on the peritoneal wall and in the peritoneal cavity, much
like human ovarian cancer. For testing IONP biodistribution, Ffab-CMD, Bfab-CMD, Ffab-BNF, or Bfab-BNF
were injected IP at 750 µg iron in 400 µL PBS on day 18.
Approximately 18 hours after IONP injection, mice were
euthanized using CO2 according to the IACUC approved
protocol, followed by perfusion with 20 mL of PBS from
the left ventricle. Fat, spleen, kidney, liver, and tumors
growing on the peritoneal wall and in the peritoneal cavity
were harvested in pre-weighed conical tubes. Each tissue
was weighed and subjected to acid digestion using 3–10 mL
of trace metal grade acid mixture (9:1 HNO3:HCl; Thermo
Fisher Scientific) at 90°C for 1 hour. A 0.5 mL aliquot of
30% trace metal H2O2 (GFC Chemicals, Powell, OH, USA)
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was then added, and the samples were diluted to 15–50 mL
total volume with double-distilled water. Dartmouth Trace
Element Analysis Core Facility measured each digest tissue’s iron content using inductively coupled plasma mass
spectrometry (ICP-MS).
In addition to quantitative iron analysis of tissues, qualitative histology was performed on representative tumor sections. Approximately 18 hours after IONP injection, mice
were euthanized using CO2, and tumor cells on the peritoneal
wall and cavity were harvested and embedded in paraffin.
Paraffin sections (5 µm) on microscope slides were heated
in an oven set at 79°C for 30 minutes and deparafinized.
Samples were stained for iron using a Gomori Prussian blue
iron stain kit (Newcomer Supply, Middleton, WI, USA) following the manufacturer’s protocol, and were then mounted
with Permount™ (Thermo Fisher Scientific). Samples were

CH3
H 3C

N

N

O
NH2

Results
Fab design, production, and analysis
The workflow for IONP functionalization and subsequent
conjugation with the engineered antibodies is shown in
Figure 1. The two antibody fragments, Farletuzufab (Ffab),
targeting the FOLRα cancer antigen, and Botulifab (Bfab),
targeting the negative control protein botulinum toxin, were
constructed such that each retained an unpaired C-terminal

Fab
Expression + purification

CMD IONPs

O

immersed in hematoxylin (Thermo Fisher Scientific) for
5 minutes, washed with water, immersed in eosin (Fisher,
Pittsburgh, PA) for 2 minutes, and washed with water again.
Slides were dehydrated with increasing concentrations of
ethanol and then xylene, and were mounted with Permount.
Tissue histology was performed with the help of Dartmouth
Pathology Translational Research Services.

O

O
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N=C=N

BNF IONPs
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Sulfo-GMBS
(382.28 Da)

L-cysteine
(121.16 Da)

EDC and N-(2-aminoethyl)maleimide
(254.16 Da)
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CMD IONPs
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O

O

H
N

N
O

O

Maleimide-PEG2-biotin
(526 Da)

Fab capped with
Maleimide-PEG2-biotin

Fab-coated
BNF IONPs

Figure 1 Schematic of workflow for fab and IONP functionalization.
Notes: Monomeric Ffab and Bfab are subjected to reduction/activation using 20 mM cysteine followed by conjugation with maleimiede-PEG2-biotin or maleimide-activated
IONPs. Two IONP types were examined in this study: Dartmouth CMD and commercial BNF, which were functionalized with maleimide groups using EDC and N-(2aminoethyl) maleimide, or sulfo-GMBS, respectively.
Abbreviations: IONP, iron oxide nanoparticle; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab;
Bfab, anti-botulinum toxin fab fragment; PEG2, polyethylene glycol 2; CMD, carboxymethyl-dextran; BNF, bionized nanoferrite; EDC, 1-ethyl-3-(3-dimethylaminopropyl)
carboiimide; sulfo-GMBS, N-(γ-maleimobutyryloxy) sulfosuccinimide ester.
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cysteine on the heavy chain. This design ultimately enabled
site-specific conjugation to either maleimide-PEG2-biotinor maleimide-functionalized IONPs. Ffab and Bfab were
expressed in HEK 293 cells, and the desired fab monomers
were isolated by Kappa select affinity purification followed
by size exclusion chromatography (Figure S1A, B).

Mass spectral analysis of Ffab and Bfab
The identities of monomeric Ffab and Bfab were verified by
liquid chromatography-mass spectrometry (LC-MS). The
base peak of Ffab (expected [exp] =47,989 Da, observed
[obs] =48,109 Da) was 120 Da heavier than expected, suggesting the presence of a cysteine adduct (Figure S1C).
Bfab, on the other hand, exhibited a +103 Da difference
(exp =48,528 Da, obs =48,631 Da), the source of which
was not immediately obvious (Figure S1D). Upon reductive
activation with free cysteine, Ffab showed the expected peak
at 47,989 Da as well as peaks corresponding to free heavy
chain (exp =24,239 Da, obs =24,239 Da) and free light chain
(exp =23,750 Da, obs =23,751 Da) (Figure S1E). Similar
results were observed previously with a fab fragment of
Trastuzumab, and it was determined then that the free heavy
and light chains resulted from transient reduction of the
intrachain disulfide bond, with no significant loss of binding
activity or specificity.26 Cysteine-activated Bfab exhibited
a -17 Da difference relative to the theoretical molecular
mass (exp =48,528 Da, obs =48,511 Da). This difference is

$
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consistent with N-terminal deamination of glutamine,28 and
it explains the observed mass of the pre-activation material
(ie, a de-aminated cysteine adduct yields +103 Da). Similar
to cysteine-activated Ffab, the activated Bfab exhibited two
lower molecular mass peaks that corresponded with free
heavy and light chains (Figure S1F).
To assess the chemical reactivity of the engineered
antibody fragments, conjugation reactions were performed
with maleimide-PEG2-biotin. As expected, the reactions
resulted in addition of one biotin moiety (+526 Da) to each
of the intact fab antibodies (Figure S1G, H), and this observation demonstrated that the engineered fab was amenable to
site-specific conjugation as designed. The free heavy chain
and light chain of both activated antibody preparations also
reacted as expected, with the addition of one biotin moiety
to the light chain and two to the heavy chain. These results
are also consistent with previous work on the Trastuzumab
fab antibody fragment.26
Ffab and Bfab purities were evaluated by SDS-PAGE.
Under reducing conditions (presence of 50 mM dithiothreitol), the heavy and light chains of both Ffab and Bfab
migrated as a single 25 kDa band (Figure 2A, B; lane 1).
In non-reducing conditions (no dithiothreitol), Ffab and
Bfab migrated predominantly as the expected 48 kDa
band, although less intense low molecular weight bands
corresponding to free heavy chain and light chain were
also observed (Figure 2C, D; lane 1). Following reductive
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N'D
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/LJKWFKDLQ

Figure 2 Characterization of Ffab and Bfab antibody fragments.
Notes: Reducing SDS-PAGE gels of (A) purified Ffab and (B) purified Bfab, stained with Coomassie brilliant blue. Non-reducing SDS-PAGE gel of (C) purified Ffab and (D)
purified Bfab, stained with Coomassie brilliant blue. Lane 1 represents size exclusion-purified Ffab or Bfab, lane 2 is Ffab or Bfab after cysteine reductive activation, and lane
3 is Ffab or Bfab after maleimide-PEG2-biotin conjugation.
Abbreviations: SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered
from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; PEG2, polyethylene glycol 2.
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activation of both Ffab and Bfab, much of the intact fab
band at 48 kDa was shifted to the lower molecular weight
bands for free heavy chain and light chain (Figure 2C, D;
lane 2), which was consistent with the appearance of these
species during LC-MS analysis. Upon conjugation to
maleimide-PEG2-biotin, substantial portions of the intact
fabs were reconstituted, although bands for free heavy
and light chain remained evident (Figure 2C, D; lane 3).
The LC-MS analysis had identified heavy and light chain
species in which the cysteines involved in interchain disulfide
bond formation had been capped with maleimide-PEG2biotin, and the corresponding free heavy and free light chain
bands in the SDS-PAGE of biotinylated fabs corroborated
that result (ie, maleimide-capped light and heavy chains are
unable to reform intrachain disulfide bonds). We emphasize
again that previous studies have shown that analogous,
reduced yet intact fabs retain the binding activity and efficiency of their disulfide bonded counterparts.26,29

Bfab-maleiemide-PEG2-biotin was observed with rFOLRα
using the same streptavidin biosensors tips (data not shown).
In aggregate, the quantitative binding studies with rFOLRα
demonstrated that the engineered Ffab retained good binding
affinity to rFOLRα, to which the parental Farletuzumab IgG
was found to have a KD =2 nM.20
In addition to binding recombinant protein, it was critical
that the engineered Ffab selectively bind the FOLRα surface
protein in its native context. To assess cellular binding, the
biotinylated Ffab and Bfab antibodies were assayed by flow
cytometry using live human KB and SKBR3 cancer cells,
where the former overexpress both FOLRα and human
epidermal growth factor receptor 2 (HER2), and the latter overexpresses HER2 only. Ffab was found to exhibit
high apparent binding affinity for KB cells (EC50 =13 nM),
whereas no substantial binding was observed on SKBR3
cells (Figure 3B). As expected, the negative control Bfab
failed to bind either KB or SKBR3 tumor cells (Figure 3B).
Thus, the Ffab antibody efficiently targeted cancer cells in
a FOLRα-dependent fashion.

Ffab binds specifically to FOLRα
Binding of Ffab and Bfab to recombinant FOLRα (rFOLRα)
was initially analyzed by ELISA. The biotin-labeled Ffab
fragment exhibited a half maximal effective concentration
(EC50) of 12 nM, whereas no binding was observed with the
biotinylated Bfab control (Figure 3A). Additionally, more
detailed rFOLRα binding kinetics were analyzed by biolayer
interferometry (Figure S2). Ffab-maleimide-PEG2-biotin
was immobilized on streptavidin biosensor tips and assayed
with rFOLRα protein. The equilibrium dissociation constant
for Ffab (KD =14 nM) was comparable to the EC50 obtained
by ELISA (Figure 3A). Importantly, no detectable binding of

Having validated Ffab binding affinity and specificity for
soluble and cell surface FOLRα, the antibody fragment
was conjugated to both CMD and BNF-maleimide-IONPs
that differ in nanoscale structure and carbohydrate coating
(Figure S3). These conjugations yielded Ffab-CMD and FfabBNF constructs that differed in size (~120 nm vs ~190 nm
hydrodynamic diameter, respectively) (Figure S4) and number of antibody-targeting moieties (~50 vs ~500 moieties,
respectively; Table 1).
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Figure 3 Binding analysis of Ffab and Bfab antibody fragments.
Notes: (A) Representative ELISA binding profile of Ffab (closed square) and Bfab (open circle) with rFOLRα protein. (B) Representative cell-based ELISA for Ffab (closed
symbols) and Bfab (open symbols) binding to FOLR+/HER2+ KB cells (squares) or FOLR-/HER2+ SKBR3 cells (triangles).
Error bars represent standard deviation from technical triplicates.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum
toxin fab fragment; ELISA, enzyme-linked immunosorbent assay; FOLR, folate receptor; rFOLRα, recombinant folate receptor alpha; HER2, human epidermal growth factor
receptor 2.
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Particle design

Hydrodynamic diameter (nm)

PDIa

Zeta potential (mV)

Mean fab/IONPs

CMD*-Mal
Bfab-CMD
Ffab-CMD
BNF*-Mal
Bfab-BNF
Ffab-BNF

115
118
120
143
190
182

0.146
0.186
0.230
0.146
0.400
0.324

-0.320
-0.400
-0.141
-0.170
-0.500
-0.136

N/A
50
50
N/A
500
500

Notes: aPolydispersity index; *CMD particles have a concentration of 0.5 mg of iron/mg of particles, whereas BNF particles have 0.6 mg of iron/mg of particles.
Abbreviations: IONP, iron oxide nanoparticle; PDI, polydispersity index; N/A, not applicable; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered
from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; CMD, carboxymethyl-dextran; BNF, bionized nanoferrite; Mal, maleimide.

FOLRα binding of the Ffab-CMD and Ffab-BNF constructs, and their respective Bfab-IONP negative control counterparts was evaluated by ELISA (Figure 4A, B). Compared
to the monomeric Ffab antibody, both Ffab-IONP constructs
exhibited orders of magnitude higher apparent affinities
(Ffab-BNF EC50 =0.013 nM; Ffab-CMD EC50 =0.16 nM),
which reflects avidity effects derived from the nanoparticles’
polyvalent nature. Conversely, no substantial binding was
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observed with the Bfab-BNF or Bfab-CMD negative control nanoparticles. These results demonstrated that Ffab
binding of rFOLRα was not compromised during IONP
conjugation, and that the Bfab-IONP controls had no inherent affinity for the recombinant receptor. It is noteworthy
that the larger Ffab-BNF particles exhibited 10-fold higher
apparent affinity compared to the Ffab-CMD particles. This
effect likely results from their 10-fold difference in number
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Table 1 Biophysical and biochemical characterization of IONP constructs
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Figure 4 In vitro binding studies of Ffab-IONPs and Bfab-IONPs.
Notes: (A) Dose–response binding curves for Ffab-CMD (closed square) and Bfab-CMD (open circles) with rFOLRα protein. (B) Dose–response binding curves for FfabBNF (closed square) and Bfab-BNF (open circles) with rFOLRα protein. (C) Binding of FOLRα+ KB cancer cells by Ffab-CMD and Bfab-CMD dosed at 35 µg/mL (0.6 nM). (D)
Binding of FOLRα+ KB cancer cells by Ffab-BNF and Bfab-BNF dosed at 35 µg/mL (0.035 nM). Error bars represent standard deviation from technical triplicates. ***P0.001,
two-tailed unpaired t-test.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin
fab fragment; IONP, iron oxide nanoparticle; CMD, carboxymethyl-dextran; rFOLRα, recombinant folate receptor alpha; BNF, bionized nanoferrite, NP, nanoparticle.
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of conjugated antibodies (500 vs 50 antibodies for BNF
and CMD, respectively; Table 1). The higher maximum
signal of the Ffab-BNF particles is likely due, in part, to
their higher apparent affinity, and in part, due to the fact that
BNF nanoparticles possess greater iron content than CMD
nanoparticles (0.6 mg iron/mg of particles vs 0.5 mg iron/mg
of particles, respectively).
The targeting capacity of the nanoparticles was further
assessed using FOLRα-positive cancer cells. Both Ffab-CMD
and Ffab-BNF efficiently bound adherent KB tumor cells
during an 8-hour incubation in complete medium, whereas
the Bfab-targeted IONPs showed little to no cellular association (Figure 4C, D). Importantly, the greater accumulation of
Ffab-CMD (0.6 nM) compared to Ffab-BNF (0.035 nM) is
due to the experimental design, where both particle types were
incubated at a mass concentration of 35 µg/mL, yielding a
17-fold greater molar concentration of CMD nanoparticles.
As part of the KB cellular binding studies, the subcellular localization of Ffab-CMD and Ffab-BNF conjugates
was analyzed by transmission electron microscopy (TEM).

$

TEM micrographs showed that, following an 8-hour cellular
incubation in vitro, Ffab-CMD and Ffab-BNF can be found
accumulated on both the cell membrane as well as within
intracellular vesicles (Figure 5A, B, D, E). Consistent with
the negligible binding of Bfab-CMD and Bfab-BNF observed
above (Figure 4C, D), no Bfab-targeted particles could be found
in corresponding TEM images (Figure 5C, F). In aggregate,
these results demonstrate specific and efficient targeting of
FOLRα-positive cancer cells by Ffab-CMD and Ffab-BNF, and
additionally, they reveal that the Ffab-targeting moiety facilitates cellular internalization of both nanoparticle constructs.

In vivo tumor targeting of IONPs
Based on the in vitro performance of targeted Ffab-IONPs,
we anticipated that these nanoparticle constructs might also
exhibit enhanced tumor localization in vivo. To test this
hypothesis, a single dose (750 μg of iron) of each IONP was
administered intraperitoneally (IP) to NSG mice bearing peritoneal tumors derived from human KB cells. Approximately
18 hours post-injection, tumors, surrounding fat, and other
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Figure 5 TEM imaging of Ffab-IONP and Bfab-IONP subcellular localization following in vitro binding to FOLRα+ KB cancer cells.
Notes: Magnification of 25,000× showing the binding of (A) Ffab-CMD and (D) Ffab-BNF on the KB cell surface (arrows). Magnification of 10,000× showing (B) Ffab-CMD
and (E) Ffab-BNF within intracellular vesicles (arrows). Magnification of 25,000× showing no evidence of nanoparticles on KB tumor cells treated with (C) Bfab-CMD or
(F) Bfab-BNF. Scale bars are 100 nm (A, C, D and F) and 500 nm (B and E).
Abbreviations: TEM, transmission electron microscopy; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody
Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; IONP, iron oxide nanoparticle; CMD, carboxymethyl-dextran; rFOLRα, recombinant folate receptor alpha;
BNF, bionized nanoferrite; NP, nanoparticle.
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Discussion
IONPs represent multi-functional nanomaterials with enormous value in the field of oncology. They have undergone
extensive development as contrast agents for imaging, as
cell capture reagents for diagnostics, as controlled release
drug delivery platforms, and as energy converters for heat
deposition in magnetic hyperthermia.7,9,10,30–54 In all of these
applications, the ultimate utility of IONPs is critically dependent on differential association with malignant vs healthy
cells; selective partitioning to the tumor environment and/or
tumor cells is the key to enabling effective IONP diagnostics
and therapeutics. In the current study, we have examined
molecular targeting of IONPs to FOLRα-positive cancers
using an engineered antibody fragment.
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in the liver (Figure 6C). While the identity of the targeting
antibody did not substantially influence liver accumulation,
CMD-based nanoparticles showed a significantly higher
liver concentration than did BNF nanoparticles (~40%
injected dose vs ~20%, respectively). When compared to
PBS-injected animals, animals treated with IONPs experienced no significant increase in splenic or kidney iron levels
(Figure 6D and E, respectively).

Ffab-BNF

major organs in the abdominal cavity were harvested, and
IONP content was quantified by ICP-MS (Figure 6 shows
total tissue iron; Figure S5 shows tissue iron concentration). As seen in the in vitro cellular binding studies, the
Bfab-CMD and Bfab-BNF negative controls failed to show
significant iron accumulation within in vivo tumor masses
(Figure 6A). In contrast, Ffab-BNF and Ffab-CMD yielded
statistically significant increases in tumor-associated iron
(Figure 6A), averaging ~5% or ~7%, respectively, of the
initially injected dose. Histology of tissue sections showed
the KB tumors to be largely localized on the peritoneal wall
(Figure 7A–C), and Prussian blue staining for iron was
qualitatively consistent with the ICP-MS analysis, revealing
significant iron accumulation on the surface of and within
tumors from animals treated with Ffab-BNF (compare
Figure 7F to D and E).
For both Ffab-IONPs and Bfab-IONPs, significant iron
accumulation was also noted in the peritoneal fat tissue. There
was a trend toward greater fat accumulation of Ffab-CMD
vs the other constructs (~3% of the injected dose vs ~2% for
other constructs), although the difference was only significant
in comparison to Bfab-BNF (Figure 6B). For all four particle
types, the majority of the recovered nanoparticles were found

Total iron (µg)
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C

Figure 6 In vivo biodistribution of IONPs following IP administration.
Notes: Total iron content of various tissue compartments is shown: (A) tumor; (B) fat; (C) liver; (D) spleen; and (E) kidney. Data obtained by ICP-MS from five mice
per group approximately 18 hours post-injection. Statistical significance was analyzed by one-way ANOVA with a Tukey multiple comparison post-test, and the results of
individual comparisons are provided in the tables below each graph. ****P,0.0001; ***P,0.001; **P,0.01; *P,0.05.
Abbreviations: PBS, phosphate-buffered saline; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab;
Bfab, Botulifab anti-botulinum toxin fab fragment; CMD, carboxymethyl-dextran; rFOLRα, recombinant folate receptor alpha; BNF, bionized nanoferrite; IONPs, iron oxide
nanoparticles; IP, intraperitoneal; ICP-MS, inductively coupled plasma mass spectrometry; ANOVA, analysis of variance.

FOLRα is a glycosylphosphatidylinositol-anchored
glycoprotein whose expression is generally restricted in
normal tissues, while often exhibiting high expression levels
in cancers of epithelial origin.13,14 IONPs have been targeted
to ovarian cancers via functionalization with folic acid, the
International Journal of Nanomedicine 2015:10

natural ligand of FOLRα.15 Importantly, however, folate is
an essential nutrient, and healthy cells acquire folate from
their environment via numerous high-affinity membrane
receptor proteins and transporters, including FOLRα, FOLR
beta, FOLR gamma,19 reduced folate carrier (solute carrier
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Figure 7 Histology of excised tumors from ovarian cancer model.
Notes: Representative images where the tumor and peritoneal membrane are indicated. HE of tumor sections from animals treated with (A) PBS, (B) Bfab-BNF,
or (C) Ffab-BNF. (D, E, F) Prussian blue staining of the same slides, respectively, to identify IONPs.
Abbreviations: HE, hematoxylin eosin; PBS, phosphate-buffered saline; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal
antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; IONPs, iron oxide nanoparticles; BNF, bionized nanoferrite.

19A1),55,56 and a proton-coupled folate transporter (solute
carrier 46A1).57 Agents targeted by conjugation to folic acid
can interfere with the uptake of naturally circulating folate,
and they are known to bind both FOLRα and FOLRβ, which
reduce their selectivity for cancer cells.19 On the other hand,
the monoclonal IgG antibody Farletuzumab is a highly
specific binder of FOLRα, and it has been shown to exhibit
little to no cross-reactivity with healthy cells and tissues.20
Thus, Farletuzumab, or engineered fragments thereof, represent interesting candidates for tumor-specific targeting of
IONPs.
In this study, we have demonstrated that 1) Ffab, a reformatted fragment of Farletuzumab, maintains the binding
activity and specificity of the parental monoclonal antibody;
and 2) functionalization of IONPs with Ffab substantially
increases selective iron deposition in cultured cancer cells
and in in vivo peritoneal tumors. Ffab-targeted IONPs were
constructed from two different nanoparticle foundations:
1) commercially sourced BNF particles, and 2) custom
synthesized CMD particles. The BNF particles had a larger
hydrodynamic diameter (~190 nm vs ~120 nm), contained
1.2-fold more iron per particle, and bore a 10-fold greater
number of Ffab-targeting moieties on their surface.
The distinct characteristics of the two IONP platforms
resulted in differential targeting efficiency in vitro, where the
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larger Ffab-BNF particles had a 10-fold higher affinity for
rFOLRα and accumulated 10-fold more iron when used at
an equivalent molar concentration. Conversely, when used at
equal mass concentrations, Ffab-CMD particles accumulated
approximately 2-fold more iron during in vitro incubation
with FOLRα-positive cancer cells. Importantly, however,
both Ffab-BNF and Ffab-CMD outperformed controls
targeted to an irrelevant protein, and both Ffab-targeted
IONP types resulted in substantial cellular internalization.
Internalization of antibody-targeted IONPs has been reported
previously.26,58,59 and the capacity to internalize IONPs via
FOLRα could have important implications for hyperthermia
or cytotoxic drug delivery to ovarian cancers.3,60
In contrast to their differential in vitro binding activities,
in vivo administration of the two IONP platforms at a fixed
iron dose showed no significant difference with respect to
tumor homing in a murine model of ovarian cancer. This
observation underscores the fact that, with respect to cancerspecific targeting, the results of in vitro experiments cannot
be readily extrapolated to predict in vivo performance.
In a previous murine model study of breast cancer, we
showed that IONP size was the dominant determinant of
tumor localization following intravenous administration of
either targeted or non-targeted constructs.26 Interestingly,
in that study, smaller 30 nm IONPs localized to the tumor
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compartment, whereas larger 100 nm IONPs did not. Conversely, larger 100 nm IONPs localized almost exclusively
to the liver, whereas smaller 30 nm IONPs manifested
significantly lower liver accumulation. In the current study,
IONP size also correlated with liver sequestration, but in
an inverted fashion: smaller 120 nm IONPs showed greater
liver accumulation than larger 180 nm IONPs (40% vs 20%
of the injected dose, respectively).
Unfortunately, numerous confounding factors make it difficult to draw meaningful conclusions from comparison of the
current ovarian cancer model and the previous breast cancer
model,26 (eg, different nanoparticle types, nanoparticle sizes,
cancer cell lines, the nature of the models, the route of IONP
administration, etc). Nonetheless, the results reported here
provide important insights into the biodistribution of IONPs
following IP administration. In particular, molecular targeting of FOLRα resulted in a significant tumor accumulation
of IONPs. It bears noting that, in larger tumor cross-sections,
IONPs exhibited highly concentrated accumulation in limited
areas, but smaller, punctate accumulations were also seen
distributed throughout the cross-sectional fields of view
(Figure 7F). This non-uniform but tumor-wide deposition
is more analogous to results seen with intravenous IONP
administration than with direct tumor injection, where the
former has recently been shown to achieve better efficacy
in thermal ablation treatments.49 Specifically, in their work,
Huang and Hainfeld note that uniform IONP distribution
throughout the tumor is not required to achieve therapeutic
heating, but rather tumor-wide deposition and encasement
is adequate.49
The 5%–7% of initially injected IONP dose that was found
in the tumor in the current study equaled that of a previous
study that leveraged tumor-associated peritoneal phagocytes
to localize non-targeted IONPs to ovarian tumor masses.6 It is
unclear whether the NSG mouse model of the current study
possesses similar tumor-associated peritoneal phagocytes,
but the lack of any negative control Bfab-targeted IONPs in
the tumor mass might suggest that phagocyte-mediated trafficking of IONPs to the tumor is compromised in the NSG
model. If true, we speculate that the use of FOLRα-targeted
IONPs in a suitable immuno-competent model might result
in additive tumor homing, and such a substantial IONP tumor
accumulation would bode well for potential diagnostic and
therapeutic applications.
In summary, in the present study, we have demonstrated
molecular targeting of IONPs to the FOLRα cancer marker.
Our targeting agent is based upon a clinically validated
monoclonal antibody that has exquisite specificity for
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FOLRα vs other folate receptors and transporters, and
this selectivity may enable enhanced tumor accumulation
relative to alternative FOLRα targeting strategies. These
FOLRα-specific iron oxide nanomaterials may ultimately
prove useful in advancing diagnosis, imaging, and therapy
of ovarian cancers.
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Figure S1 Purity and identity analysis of recombinant fab fragments.
Notes: Size exclusion purification chromatograms of (A) Ffab and (B) Bfab. The blue curves represent UV absorbance at 280 nm, and dashed lines represent the collected
monomeric Ffab and Bfab fractions. LC-MS of monomeric SEC fractions from (C) Ffab and (D) Bfab. LC-MS of monomeric (E) Ffab and (F) Bfab following cysteine activation.
LC-MS of (G) activated monomeric Ffab and (H) activated monomeric Bfab following conjugation to maleimide-PEG2-biotin. The masses of 24,276 and 23,931 Da correspond
to the addition of one maleimide-PEG2-biotin molecule (+526 Da) to the light chains of Ffab and Bfab, respectively. The masses of 25,291 and 26,158 Da correspond to the
addition of two maleimide-PEG2-biotin molecules (+1,052 Da) to the heavy chains of Ffab and Bfab, respectively. The masses of 48,515 and 49,037 Da correspond to the
addition of one maleimide-PEG2-biotin molecule (+526 Da) to intact Ffab and Bfab, respectively.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum
toxin fab fragment; UV, ultraviolet; PEG2, polyethylene glycol 2; SEC, size-exclusion chromatography; LC-MS, liquid chromatography-mass spectrometry.
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Figure S2 Bio-layer interferometry binding analysis of Ffab antibody fragment.
Notes: Sensorgrams of soluble rFOLRα binding to Ffab immobilized on ForteBio streptavidin biosensor tips. Blue curve indicates measured binding kinetics and red line
indicates best-fit curve from kinetic modeling. The best-fit on rate, off rate, and equilibrium dissociation constants are provided below the sensorgrams.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum
toxin fab fragment; rFOLRα, recombinant folate receptor alpha; sec, seconds.
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Figure S3 TEM pictures of bulk IONPs.
Notes: (A) 15,000× magnification of commercial bionized nanoferrite (BNF) particles and 71,000× magnification (inset). (B) 19,500× magnification of the Dartmouth CMD
particles and 71,000× magnification (inset).
Abbreviations: TEM, transmission electron microscopy; IONPs, iron oxide nanoparticles; CMD, carboxymethyl-dextran.
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Figure S4 IONP size distribution profile.
Notes: As measured by dynamic light scattering, the intensity size distributions of (A) CMD and (B) BNF IONPs are characterize by mean peaks of 118 nm and 172 nm,
respectively. The red lines are maleimide-conjugated IONPs, the light blue lines are negative control Botulifab-conjugated IONPs, and the dark blue lines are the Farletuzufabconjugated IONPs.
Abbreviations: IONPs, iron oxide nanoparticles; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab;
Bfab, Botulifab anti-botulinum toxin fab fragment; BNF, bionized nanoferrite; CMD, carboxymethyl-dextran; Mal, maleimide.
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Figure S5 In vivo biodistribution of IONPs.
Notes: Tissue iron concentration (ie, per gram of tissue) is shown for various compartments: (A) tumor; (B) fat; (C) liver; (D) spleen; and (E) kidney. Data obtained by
ICP-MS from five mice per group approximately 18 hours post-injection. Statistical significance was analyzed by one-way ANOVA with a Tukey’s multiple comparison posttest, and the results of individual comparisons are provided in the tables below each graph. ****P,0.0001; ***P,0.001; **P,0.01; *P,0.05.
Abbreviations: IONPs, iron oxide nanoparticles; ICP-MS, inductively coupled plasma mass spectrometry; ANOVA, analysis of variance; PBS, phosphate-buffered saline;
BNF, bionized nanoferrite; CMD, carboxymethyl-dextran; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody
Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment.
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